Horizon Space Acquisition II Corp. Ordinary shareSLBT

Early-stage biotechnology holding company advancing scalable cell-therapy platforms for global immune-based medicine. In the global oncology market, cell therapy is widely recognized as one of the most transformative approaches in modern medicine. Despite its clinical promise, however, the industry has yet to scale into a true global platform due to three core limitations: lack of standardization, limited manufacturing capacity, and extremely high.

slbtgroup.com